Issue Date: October 16, 2017
Pfizer mulls sale of consumer business
Pfizer is considering selling or spinning off its consumer health care division, one of the world’s biggest makers of over-the-counter drugs. Stock analysts expect the unit, which had sales last year of $3.4 billion, to fetch up to $15 billion. Industry watchers say the potential move comes as Pfizer considers a sizable acquisition to bolster its research-driven drug arm. Merck KGaA put its consumer products business up for sale last month.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society